Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.56 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.53 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.53 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6181139 | 0.98 | GNAO1 (0.56) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL7136176 | 0.94 | GNAO1 (0.61) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL10442381 | 0.92 | GNAO1 (0.65) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL7130155 | 0.92 | GNAO1 (0.65) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL7133353 | 0.92 | GNAO1 (0.65) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL7138426 | 0.92 | GNAO1 (0.65) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL7133428 | 0.92 | GNAO1 (0.65) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| Hydrochloric Acid SCHEMBL10442919 | 0.90 | GNAO1 (0.68) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL856491 | 0.88 | NCF1 (0.47) | NCF1GNAO1GNAI3GNAI1KCNH2 | |
| SCHEMBL1540650 | 0.87 | NCF1 (0.60) | NCF1GNAO1GNAI3GNAI1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107973789-B | Epoxidized soybean oil toughening agent and preparation method and application thereof | 万华化学集团股份有限公司 | 2020-06-16 | — | — | CN | claimed |
| CN-106398080-B | A kind of ammonium cross-linking type block copolymer/graphene composite material and preparation method thereof | 北京化工大学 | 2018-12-04 | — | — | CN | claimed |
| CN-106398080-A | Aminated cross-linked segmented copolymer/graphene composite material and preparation method thereof | 北京化工大学 | 2017-02-15 | — | — | CN | claimed |
| EP-0927163-B1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM PLC (GB) | 2007-03-28 | — | — | EP | claimed |
| EP-1097136-B1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | claimed |
| CN-1102927-C | Preparation method of 1-butyl-4-piperidyl methylamine | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | CN | claimed |
| US-6331631-B1 | Preparation of 1-butyl-4-piperidinylmethylamine | SMITHKLINE CORPORATION P.L.C. (GB) | 2001-12-18 | — | — | US | claimed |
| US-20010031751-A1 | (+/-)-n-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-4 -hydroxy-2h-(1,3)oxazino(3,2-alpha)indole-10-carboxamide as seretonin receptor antagonist; gastrointestinal, cardiovacular and central nervous system disorders | SMITHKLINE BEECHAM P.L.C. | 2001-10-18 | — | — | US | claimed |
| EP-0922048-B1 | PROCESS FOR THE PREPARATION OF N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-15 | — | — | EP | claimed |
| EP-1037894-A1 | PHARMACEUTICALS | SMITHKLINE BEECHAM PLC (GB) | 2000-09-27 | — | — | EP | claimed |
| CN-1230179-A | Prepn. of 1-butyl-4-piperidinylmethylamine | SMITHKLINE BEECHAM PLC (GB) | 1999-09-29 | — | — | CN | claimed |
| EP-0927163-A1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | EP | claimed |
| WO-1999029697-A1 | PHARMACEUTICALS | SMITHKLINE BEECHAM PLC (GB) | 1999-06-17 | — | — | WO | claimed |
| WO-1998011067-A1 | PREPARATION OF 1-BUTYL-4-PIPERIDINYLMETHYLAMINE | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-03-19 | — | — | WO | claimed |
| JP-10316661-A | — | — | None | — | — | JP | disclosed |
| CN-119528174-A | Modified MWW molecular sieve and preparation method thereof, xylene isomerization catalyst and preparation method and application thereof | 中国石油化工股份有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-111348994-B | Process for preparing 4-methyl-5-nonene and 4-methyl-5-nonanol | 信越化学工业株式会社 | 2023-10-27 | — | — | CN | disclosed |
| CN-1073173-A | Preparation method as the compound of 5-hydroxytryptamine receptor antagonist | SMITHKLINE BEECHAM PLC (GB) | 1993-06-16 | — | — | CN | disclosed |
| WO-1993005038-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-18 | — | — | WO | disclosed |
| WO-1993003725-A1 | 5-HT4 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031751-A1 | (+/-)-n-((1-butyl-4-piperidinyl)methyl)-3,4-dihydro-4 -hydroxy-2h-(1,3)oxazino(3,2-alpha)indole-10-carboxamide as seretonin receptor antagonist; gastrointestinal, cardiovacular and central nervous system disorders | HTR5A, HTR3A, HTR4 | NCF1 4725/4885GNAO1 509/4885GNAI3 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.